ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug

• The drug is specifically approved to treat blastic plasmacytoid dendritic cell neoplasm (an ultra-rare and aggressive type of blood and bone marrow cancer). 
• In clinical trials, nearly 70% of patients who had received no prior therapy achieved a complete remission 
• The approval comes with a "Boxed Warning"—FDA’s safety alert—due to the risk of severe hepatotoxicity (liver damage).

AbbVie (ABBV) share price gained on Wednesday after U.S. Federal health regulators approved the company’s drug tailored to combat an ultra-rare, aggressive form of blood cancer. 

The Food and Drug Administration announced its approval of pivekimab sunirine-pvzy (sold under the brand name Decnupaz, made by AbbVie) on Wednesday. The drug is classified as an antibody-drug conjugate (a targeted therapy that pairs a cancer-seeking antibody with a potent cell-killing drug), specifically designed to bind to a protein commonly found on these cancer cells. 

ABBV Clinical Trial Success 

The FDA based its decision on data from an open-label (a study where both doctors and participants know which treatment is being given), single-arm clinical trial known as CADENZA. The study tracked both newly diagnosed patients and those with recurrent cancer.

Among 33 patients who were treatment-naïve (patients who have never received any previous medical treatment for their illness), the results were highly encouraging. Roughly 69.7% of these individuals achieved a complete remission or a clinical complete remission (a state where tumors shrink completely and blood counts normalize, even if minor skin lesions remain). For these patients, the response lasted an average of 9.7 months.

The drug also showed measurable, though lower, activity in patients with relapsed or refractory (cancer that has returned or stopped responding to prior treatments) forms of the disease. In that group of 51 patients, 15.7% achieved a complete remission, lasting an average of 9.2 months.

ABBV Safety Warnings 

The FDA required the medication to feature a Boxed Warning—the agency's most prominent safety alert—warning doctors and patients about the potential for severe hepatotoxicity (liver damage).

Specifically, the treatment can trigger hepatic veno-occlusive disease (a rare, life-threatening condition where the small blood vessels inside the liver become blocked and inflamed).

ABBV Retail View 

Retail sentiment on Stocktwits was “neutral” with “high” message volumes. 

ABBV stock has lost 6.4% year-to-date. 

Read More: Uber Reportedly Adds To Its Delivery Hero Stake At €12B Valuation

For updates and corrections, email newsroom[at]stocktwits[dot]com.